H-076
9-Hydroxyrisperidone solution
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
等级
certified reference material
质量水平
表单
liquid
特点
Snap-N-Spike®/Snap-N-Shoot®
包装
ampule of 1 mL
制造商/商品名称
Cerilliant®
浓度
1.0 mg/mL in methanol
技术
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
应用
clinical testing
包装形式
single component solution
运输
wet ice
储存温度
−20°C
SMILES字符串
CC1=C(CCN2CCC(CC2)c3noc4cc(F)ccc34)C(=O)N5CCCC(O)C5=N1
InChI
1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3
InChI key
PMXMIIMHBWHSKN-UHFFFAOYSA-N
基因信息
human ... DRD2(1813), HTR2A(3356)
一般描述
A Snap-N-Spike® Reference Solution suitable to use in LC/MS or GC/MS applications for urine drug testing, clinical toxicology, and forensic analysis. Also known as paliperidone, 9-Hydroxyrisperidone is sold under the brand name Invega, an atypical antipsychotic used for acute and maintenance treatment of schizophrenia. The drug is also the primary metabolite of risperidone, marketed as the atypical antipsychotic Risperdal®.
法律信息
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Risperdal is a registered trademark of Johnson & Johnson
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
警示用语：
Danger
危险分类
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
靶器官
Eyes
储存分类代码
3 - Flammable liquids
WGK
WGK 1
闪点(°F)
49.5 °F - closed cup
闪点(°C)
9.7 °C - closed cup
法规信息
危险化学品
此项目有
Possible paliperidone-induced neuroleptic malignant syndrome: a case report.
Armağan Özdemir et al.
The Journal of neuropsychiatry and clinical neurosciences, 24(3), E22-E23 (2012-10-06)
N Thavichachart et al.
International journal of clinical practice, 66(10), 969-975 (2012-09-22)
To examine the demographic and psychopathological characteristics of the treatment discontinuation group compared with patients who completed with paliperidone ER treatment for 6 months. A total of 984 patients meeting the DSM-IV criteria for schizophrenia who switched their antipsychotics were
Rabbit syndrome following discontinuation of paliperidone in a patient with schizoaffective disorder.
Chih-Sung Liang et al.
Journal of clinical psychopharmacology, 32(5), 720-721 (2012-08-29)
Treatment options for residual insomnia in schizophrenia.
Lone Baandrup et al.
Acta psychiatrica Scandinavica, 127(1), 81-82 (2012-10-31)
Paliperidone as an alternative for risperidone in a case of schizophrenia with retrograde ejaculation.
Arun Kandasamy
The Journal of neuropsychiatry and clinical neurosciences, 24(3), E17-E18 (2012-10-06)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持